Welcome to our dedicated page for Deciphera Pharmaceuticals news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals stock.
Deciphera Pharmaceuticals, Inc. (symbol: DCPH) is a biotechnology company founded in 2003 with a deep scientific understanding of kinase inhibitors. Based in Boston, with research capabilities near the University of Kansas, Deciphera specializes in developing advanced kinase-inhibiting drugs for cancer and immunological diseases. The company has identified small molecule leads for over 50 kinase targets and has built a robust pipeline of drug candidates, including three clinical-stage and two research-stage programs.
The company's lead drug candidate, DCC-2618, is designed to inhibit mutant or amplified KIT and Pdgfra kinases, which drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, Deciphera is developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib, which are focused on treating different types of cancers.
Geographically, Deciphera's operations are concentrated in the United States. The company has recently achieved significant milestones, including the successful completion of a tender offer by Ono Pharmaceutical Co., Ltd. to acquire all outstanding shares of Deciphera for approximately $2.4 billion. Following this acquisition, Deciphera became a wholly owned subsidiary of Ono, who will leverage its research and development capabilities in oncology and its sales power in Europe and the United States to expand its global presence.
The merger with Ono Pharmaceutical marks a new phase for Deciphera, where the combined expertise and resources are expected to accelerate the growth of their pipeline and contribute significantly to the global fight against cancer and other diseases.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announces Steve Hoerter, President and CEO, will join a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021, at 1:50 PM ET in a virtual format.
A live webcast will be available on the company’s website, with a replay accessible for 90 days after the presentation. Deciphera focuses on developing innovative medicines for cancer treatment, leveraging its proprietary switch-control kinase inhibitor platform. Their product, QINLOCK, is FDA-approved for fourth-line gastrointestinal stromal tumor treatment.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 4:20 PM ET. The event will be held virtually, and a live webcast can be accessed on the Company’s website under the 'Investors' section. Additionally, the webcast will be available for replay for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, including QINLOCK, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST).
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported fourth quarter 2020 financial results, achieving $19.5 million in net product revenue from QINLOCK, up from $0 in Q4 2019. The company's total revenue for 2020 was $42.1 million, driven by increased sales of QINLOCK. R&D expenses rose to $199 million for the year, while the net loss was $266.5 million, or $4.78 per share. Upcoming milestones include top-line results from the INTRIGUE study and potential EMA approval for QINLOCK. The company has a cash position of $561.3 million to support operations into 2022.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021, at 11:00 AM ET. This event will take place virtually, and a live webcast will be accessible on the Company’s website under the ‘Events and Presentations’ section. A replay will be available for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, with QINLOCK being its FDA-approved medication for fourth-line gastrointestinal stromal tumors (GIST).
Deciphera Pharmaceuticals (NASDAQ: DCPH) will announce its fourth quarter and full year 2020 financial results on February 9, 2021. The company's management will hold a live conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide updates. Investors can access the call by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) with conference ID 5826559. The webcast will also be available on the company’s website.
Deciphera Pharmaceuticals (NASDAQ:DCPH) has provided a corporate update highlighting key 2021 milestones alongside its participation in the J.P. Morgan Healthcare Conference. The company aims to expand the reach of its FDA-approved drug, QINLOCK, for treating gastrointestinal stromal tumors (GIST). Key objectives include reporting Phase 3 data for QINLOCK, seeking EMA approval, and presenting data for two other drug candidates, vimseltinib and rebastinib. The company aims for significant advancements in its clinical programs throughout 2021.
Deciphera Pharmaceuticals today announced that CEO Steve Hoerter will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 AM ET. A live webcast will be available on the company's website, with a replay archived for 90 days post-event.
Deciphera focuses on developing innovative cancer treatments, leveraging its proprietary switch-control kinase inhibitor platform. Its FDA-approved QINLOCK is specifically for fourth-line gastrointestinal stromal tumor (GIST) treatment, also approved in Canada and Australia.
Deciphera Pharmaceuticals (NASDAQ:DCPH) has completed target enrollment for its Phase 3 INTRIGUE clinical study, testing QINLOCK's efficacy in patients with second-line gastrointestinal stromal tumors (GIST). This randomized, global study involves 426 patients and compares QINLOCK to sunitinib. The primary endpoint is median progression-free survival (mPFS). QINLOCK is already approved for fourth-line GIST in the U.S., Canada, and Australia. Top-line results are expected in the second half of 2021, potentially establishing QINLOCK as a best-in-class treatment.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced that CEO Steve Hoerter participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place from December 1-3, 2020. The recording of the chat is now accessible on the Company's website under the 'Events and Presentations' section and will be available for 90 days. Deciphera focuses on developing innovative medicines for cancer, with QINLOCK® being its FDA-approved treatment for fourth-line gastrointestinal stromal tumor (GIST).
FAQ
What is the current stock price of Deciphera Pharmaceuticals (DCPH)?
What is the market cap of Deciphera Pharmaceuticals (DCPH)?
What does Deciphera Pharmaceuticals, Inc. specialize in?
Where is Deciphera Pharmaceuticals based?
What are the key drug candidates in Deciphera's pipeline?
What is DCC-2618 designed to treat?
Who acquired Deciphera Pharmaceuticals and for how much?
What will be the impact of the acquisition by Ono Pharmaceutical on Deciphera Pharmaceuticals?
What is the significance of Deciphera becoming a wholly owned subsidiary of Ono?
What are the research capabilities of Deciphera Pharmaceuticals?
Are Deciphera's operations limited to the United States?
What recent achievements has Deciphera Pharmaceuticals accomplished?
